Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | -571.00K | -1.81M | -685.00K | -209.00K |
EBITDA | -32.61M | -33.39M | -46.56M | -36.80M | -18.50M |
Net Income | -30.16M | -34.10M | -48.81M | -37.46M | -20.63M |
Balance Sheet | |||||
Total Assets | 45.36M | 74.37M | 118.38M | 153.22M | 21.43M |
Cash, Cash Equivalents and Short-Term Investments | 41.34M | 65.76M | 17.80M | 147.62M | 16.60M |
Total Debt | 3.85M | 6.21M | 8.03M | 2.35M | 567.00K |
Total Liabilities | 6.97M | 9.48M | 14.97M | 6.71M | 77.87M |
Stockholders Equity | 38.39M | 64.89M | 103.41M | 146.51M | -56.44M |
Cash Flow | |||||
Free Cash Flow | -24.82M | -32.20M | -39.35M | -32.28M | -18.91M |
Operating Cash Flow | -24.67M | -32.02M | -39.03M | -30.26M | -17.70M |
Investing Cash Flow | 22.44M | 38.41M | 49.95M | -143.12M | -1.40M |
Financing Cash Flow | -787.00K | -11.17M | -287.00K | 163.94K | 35.45M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
54 Neutral | $23.51M | ― | -92.35% | ― | -85.48% | 45.13% | |
52 Neutral | $7.58B | 0.48 | -62.71% | 2.36% | 15.33% | 0.41% | |
50 Neutral | $4.12M | ― | -205.75% | ― | 2552.29% | 60.70% | |
45 Neutral | $5.34M | ― | -468.00% | ― | ― | 98.55% | |
41 Neutral | $21.26M | ― | -160.26% | ― | ― | 19.21% | |
40 Underperform | $8.82M | ― | -64.18% | ― | ― | 1.00% | |
36 Underperform | $16.12M | ― | -110.70% | ― | ― | 18.61% |
On March 27, 2025, Sensei Biotherapeutics announced favorable preliminary results from the dose expansion portion of its Phase 1/2 trial for solnerstotug, a monoclonal antibody targeting VISTA, in PD-(L)1 resistant tumors. The trial showed an overall response rate nearly three times higher than historical PD-(L)1 rechallenge rates, with notable responses observed in Merkel Cell Carcinoma and MSI-H Colorectal Cancer patients. These findings suggest solnerstotug may offer a significant clinical benefit in select tumor types. The company plans to initiate a Phase 2 study in early 2026, contingent on securing sufficient capital, with ongoing analyses to optimize trial design and patient selection.